SCHEMBL970355

SCHEMBL970355

CCOC(=O)c1c(N)sc2c1CCN(C(=O)OCC)C2

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.83
MAPT P10636 11/20 0.67
GAA P10253 6/20 0.67
KDM4E B2RXH2 5/20 0.67
ALDH1A1 P00352 9/20 0.64
HPGD P15428 7/20 0.64
HSD17B10 Q99714 4/20 0.64
ALOX15 P16050 3/20 0.64
MAPK1 P28482 1/20 0.64
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
LMNA P02545 2/20 0.62
NPSR1 Q6W5P4 6/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
TSHR P16473 3/20 0.60
HTT P42858 2/20 0.60
PKM P14618 1/20 0.60
BLM P54132 1/20 0.60
GPR55 Q9Y2T6 1/20 0.60
POLB P06746 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16007549 0.93 ADORA1 (0.72) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL10856142 0.93 ADORA1 (0.72) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL6997953 0.91 ADORA1 (0.73) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL19475087 0.91 ADORA1 (0.73) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL10859421 0.91 ADORA1 (0.69) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL938054 0.91 ADORA1 (1.00) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL8288691 0.90 ADORA1 (0.68) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL937821 0.88 ADORA1 (0.65) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL4504119 0.86 ALDH1A1 (0.67) ADORA1MAPTGAAKDM4EALDH1A1
SCHEMBL6993930 0.85 MAPT (0.72) ADORA1MAPTGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
EP-2162451-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2010-03-17 EP disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed
WO-2005033102-A2 THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMPHORA DISCOVERY CORPORATION (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ADORA1 318/4885MAPT 3870/4885GAA 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.